---
title: "Delek US director William J. Finnerty disposes of 5,000 common shares worth $257,500"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291475748.md"
description: "Delek US Holdings director William J. Finnerty sold 5,000 common shares on June 29, 2026, at $51.5 per share, totaling $257,500. Following the transaction, his direct stake decreased to 34,805 shares."
datetime: "2026-07-02T00:48:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291475748.md)
  - [en](https://longbridge.com/en/news/291475748.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291475748.md)
generator: "portal-rs"
---

# Delek US director William J. Finnerty disposes of 5,000 common shares worth $257,500

-   Delek US Holdings director William J. Finnerty sold 5,000 common shares on June 29, 2026 at USD 51.5 each. \* Finnerty’s direct stake fell to 34,805 shares following the sale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delek US Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001283661-26-000012), on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [DK.US](https://longbridge.com/en/quote/DK.US.md)

## Related News & Research

- [Delek US director Vicky Sutil disposes of 6,397 common shares worth USD 457,385.50](https://longbridge.com/en/news/298517273.md)
- [Delek US EVP Special Projects Reuven Spiegel sells 7,500 shares worth $549,092.50](https://longbridge.com/en/news/297970639.md)
- [Singapore Index Fund amends trust deed to add electronic transfers, phase out cheques from Oct. 1, 2026](https://longbridge.com/en/news/298710637.md)
- [Damartex reports FY2025-26 annual results release available](https://longbridge.com/en/news/298344100.md)
- [BioLineRx outlines Phase 1/2a GLIX1 trial in recurrent high-grade glioma at EANO 2026](https://longbridge.com/en/news/298582374.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**